couple of speculative remarks too - it is probably more...

couple of speculative remarks too - it is probably more attractive for Novo Nordisk to acquire assets and allocate R&D funding to progress these de-risked assets instead of starting from scratch themselves. Such a large company doesn’t need to take this level of risk imo, small and nimble biotechs are better at this.

secondly I’ve spent some time in Denmark and it’s a very progressive place (far more so than Australia), so assuming NN’s corporate culture is distinctively danish, i wonder if they’d also be more amendable to acquiring such a “progressive” company working on CBD-based pharmaceutical products and Psilocybin research.